Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Cullinan's zipalertinib shows 30.2% intracranial response rate in Phase 2 lung cancer trial

Cullinan's zipalertinib shows 30.2% intracranial response rate in Phase 2 lung cancer trial

BitgetBitget2026/10/19 11:06
  • Cullinan Therapeutics and Taiho Oncology announced Phase 2 REZILIENT2 results showing zipalertinib activity against brain metastases in patients with mutation-defined lung cancer.
  • Patients had non-small cell lung cancer harboring EGFR exon 20 insertions or other uncommon EGFR mutations, with active central nervous system metastases.
  • Zipalertinib produced durable intracranial responses and was well tolerated, supporting continued evaluation in this difficult-to-treat population.
  • Results will be presented October 26, 2026, at the European Society for Medical Oncology Congress in Madrid.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261019022270) on October 19, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16